191 patents
Page 4 of 10
Utility
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
23 Jun 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Maria Fardis
Filed: 12 Dec 19
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
21 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Dec 21
Utility
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
14 Jun 22
Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Krit Ritthipichai, Michael T. Lotze
Filed: 5 Jan 18
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
7 Jun 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 9 Dec 21
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
31 May 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
31 May 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
31 May 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 9 Dec 21
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
24 May 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 21 Sep 21
Utility
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
5 May 22
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Lavakumar Karyampudi
Filed: 28 Feb 20
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
5 May 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Dec 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
26 Apr 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 21 Sep 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
21 Apr 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth WARDELL
Filed: 9 May 19
Utility
Treatment of NSCLC Patients Refractory for ANTI-PD-1 Antibody
21 Apr 22
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
Maria Fardis, Arvind Natarajan
Filed: 3 Sep 19
Utility
Systems and Methods for Coordinating Manufacturing of Cells for Patient-specific Immunotherapy
21 Apr 22
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 6 Jan 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
19 Apr 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 22 Jul 21
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
19 Apr 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 27 Aug 21
Utility
System and Methods for Monitoring Adoptive Cell Therapy Clonality and Persistence
14 Apr 22
Methods and systems for identifying clinically effective population of tumor infiltrating lymphocytes are disclosed.
Cecile Chartier-Courtaud, Viktoria Gontcharova
Filed: 10 Jan 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
5 Apr 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 21 Sep 21